Crescent Biopharma (FRA:C68) Buyback Yield %: 0.00 (As of Jul. 12, 2026)


FRA:C68 Crescent Biopharma Inc FRA:C68
18 GF Score
Price €14.60
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Buyback Yield %?

Crescent Biopharma FRA:C68 18 Buyback Yield % is 0.00 as of Jul. 12, 2026. GuruFocus rates FRA:C68 with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 742 Biotechnology companies, Crescent Biopharma ranks worse than 134770.75% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Crescent Biopharma's current buyback yield was 0.00%.

Crescent Biopharma Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Buyback Yield % Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Buyback Yield %
0.00 -94.98

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

FRA:C68 vs KYTX, ZURA, ARVN: Buyback Yield % Comparison

For the Biotechnology subindustry, Crescent Biopharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescent Biopharma Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's Buyback Yield % falls into.


FRA:C68
18GF Score
Crescent Biopharma Inc FRA:C68
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Crescent Biopharma's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.151 + 274.891) / 289.2465
=-94.98%

Crescent Biopharma's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 383.2925
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Crescent Biopharma (FRA:C68) has a Buyback Yield % of 0.00 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Crescent Biopharma and its competitors. According to the industry distribution chart, Crescent Biopharma ranks #999999 out of 742 companies in the Biotechnology industry.
Is Crescent Biopharma's Buyback Yield % too high?
Crescent Biopharma's current Buyback Yield % is 0.00. Based on the distribution chart, Crescent Biopharma ranks #999999 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crescent Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Buyback Yield % compare to KYTX and ZURA?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #999999 out of 742 companies for Buyback Yield %. This places Crescent Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Crescent Biopharma's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current Buyback Yield % is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
18GF Score

Get the complete analysis for FRA:C68

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price